GS-US-548-5916: Magrolimab Combinations in Recurrent or Metastatic HNSCC
Condition: Head and Neck Squamous Cell Carcinoma
Sponsor: Gilead Sciences, Inc.
Full Title
Protocol GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Eligibility/Info
Cohort 1:
Recurrent or metastatic head and neck squamous cell carcinoma that has not yet been treated in the recurrent/metastatic setting.
Eligible primary tumor sites include: oropharynx, oral cavity, hypopharynx, and larynx.
Patients in cohort 1 be randomized 1:1:1 to receive treatment with one of the following three regimens:
- Arm A: Magrolimab + Pembrolizumab + 5-FU + Platinum chemotherapy
- Arm B: Pembrolizumab + 5-FU + Platinum chemotherapy
- Arm C: Magrolimab + Zimberelimab + 5-FU + Platinum chemotherapy
Cohort 3:
Recurrent or metastatic head and neck squamous cell carcinoma that has recieved up to 2 prior lines of therapy in the recurrent/metastatic setting without a history of treatment with docetaxel.
Eligible primary tumor sites include: oropharynx, oral cavity, hypopharynx, and larynx.
All patients in cohort 3 will receive treatment with:
- Magrolimab + docetaxel
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.